Home

Deltalike

Deltalike refers to the Delta-like subfamily of Notch ligands, a group of transmembrane proteins that activate Notch signaling in adjacent cells. The term commonly describes the vertebrate proteins DLL1, DLL3, and DLL4, which belong to the Delta/Serrate/LAG-2 (DSL) family that also includes Jagged proteins (JAG1 and JAG2) as other Notch ligands.

Function and role in signaling: Deltalike ligands bind Notch receptors on neighboring cells to initiate juxtacrine

Structure and regulation: Deltalike proteins are single-pass type I transmembrane proteins with an extracellular domain containing

Clinical relevance: Abnormal deltali ke signaling is linked to developmental disorders and cancer. Mutations in DLL3

Examples: DLL1, DLL3, DLL4; related Notch ligands include JAG1 and JAG2.

signaling.
This
interaction
triggers
proteolytic
cleavages
of
Notch,
releasing
the
Notch
intracellular
domain
(NICD)
that
translocates
to
the
nucleus
and
partners
with
transcriptional
coactivators
to
regulate
target
genes.
Deltalike
signaling
influences
cell
fate
decisions
during
development
and
tissue
homeostasis,
including
neurogenesis,
angiogenesis,
and
somitogenesis.
Among
the
family,
DLL4
is
particularly
important
for
arterial
differentiation
and
vascular
development,
while
DLL1
broadly
promotes
Notch
activation
in
various
tissues.
DLL3
displays
a
somewhat
atypical
role
in
some
contexts
by
affecting
Notch
signaling
from
intracellular
compartments
rather
than
at
the
cell
surface.
the
DSL
motif
and
EGF-like
repeats,
and
a
cytoplasmic
tail
that
participates
in
regulatory
interactions.
Ligand
activity
is
regulated
by
endocytosis,
ubiquitination,
and
glycosylation,
with
E3
ligases
such
as
Mind
bomb
(MIB1/2)
and
Neuralized
modulating
ligand
availability.
Fringe
family
enzymes
can
modulate
Notch
receptor–ligand
interactions,
affecting
signaling
outcomes.
cause
spondylocostal
dysostosis;
JAG1
mutations
cause
Alagille
syndrome.
DLL4
and
DLL1
have
been
implicated
in
tumor
angiogenesis
and
cancer
progression,
making
Notch
pathway
components
targets
for
therapeutic
strategies.